• Recruiting

NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS

Updated: Sep 29

(OriCAR-017)

CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)

GPRC5D CAR T-cells (OriCAR-017)

NCT05016778: Phase 1: A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma


This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.


Sponsor:

Zhejiang University


Collaborator:

Oricell Therapeutics Co., Ltd


Location:

China, Zhejiang

The first affiliated hospital of medical college of zhejiang university

Hangzhou, Zhejiang, China, 310003

 

ClinicalTrials.gov Identifier: NCT05016778

Official Title: A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)

First Posted: August 23, 2021


Click here to see details on ClinicalTrials.gov

 

Drug: GPRC5D-CAR-T

GPRC5D CAR T-cells (OriCAR-017)

 

Meeting: 2022 ASCO Annual Meeting - Session Type: Oral Abstract Session - Session Title: Hematologic Malignancies—Plasma Cell Dyscrasia - Track: Hematologic Malignancies - Sub Track: Hematologic Malignancies - Clinical Trial Registration Number: NCT05016778

Abstract#: 8004 - Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).


Click here to read abstract details

 

ABSTRACTS & PRESENTATIONS

2022 ASCO ANNUAL MEETING - June 3-7, 2022 - McCormick Place, Chicago, IL - Hybrid Meeting

2022 ASCO Annual Meeting - Oral Abstract Session

Click here for details

 

Oricell Therapeutics


http://www.oricell.com/en/

http://www.oricell.com/en/technology/OriCAR/

 

The clinical data summary of ori-CAR-017, the original CAR-T candidate product, was selected for the oral report of the 2022 ASCO Annual Meeting

2022-04-18: Yuan Qi Bio, a biopharmaceutical company committed to becoming the global creator of innovative drugs for tumor immunology, today officially announced that the latest clinical data of its independent innovation product, OriCAR-017 for the treatment of relapsed/refractory multiple myeloma (RRMM), was successfully selected for the oral presentation session of the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, and the detailed data will be published in the form of oral reports.


Click here for details

 

EXPRESS: ONCE AGAIN ON THE WORLD STAGE, THE ORIGINAL CAR-T CLINICAL DATA WAS SELECTED FOR THE 2022 EHA ANNUAL MEETING


2022-05-06: Yuan Qi Bio, a biopharmaceutical company committed to becoming the creator of innovative drugs for tumor immunology in the world, today announced that the latest clinical data of its independent innovation product OriCAR-017 for the treatment of relapsed/refractory multiple myeloma (RRMM) appeared at the top international academic conference and was successfully selected for the 27th European Hematology Congress (27th EHA Congress) / Annual Conference in 2022, when detailed data will be released in the form of oral reports. OriCAR-017 is an innovative target CAR-T product developed by Hara Biotech based on its independent innovation oriAb and OriCAR technology platform.


Click here for details

 

RELATED GPRC5D POSTS


NCT04555551: Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma

Click here for details


NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma

Click here for details


NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia

Click here for details


NCT05509530: Phase 2: Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating RRMM

Click here for details

 

NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details




Posts Archive